BioMarin to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Thursday, November 5 at 4:30pm ET
10/22/2020 - 08:30 AM
SAN RAFAEL, Calif. , Oct. 22, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, November 5 , at 4:30 p.m. ET to discuss third quarter 2020 financial results and provide a general business update.
Dial-in Number
Replay Dial-in Number: (855) 859-2056
Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.biomarin.com
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare genetic diseases. The company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.biomarin.com . Information on BioMarin's website is not incorporated by reference into this press release.
Contacts:
Investors
Media
Traci McCarty
Debra Charlesworth
BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc.
(415) 455-7558
(415) 455-7451
http://www.prnewswire.com/news-releases/biomarin-to-host-third-quarter-2020-financial-results-conference-call-and-webcast-on-thursday-november-5-at-430pm-et-301157647.html
SOURCE BioMarin Pharmaceutical Inc.
Biomarin Pharmaceutical Inc.
BMRN Rankings
#2446 Ranked by Stock Gains
BMRN Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Novato
About BMRN
biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment
